País: Canadá
Língua: inglês
Origem: Health Canada
METHOTREXATE (METHOTREXATE DISODIUM)
AURO PHARMA INC
L04AX03
METHOTREXATE
2.5MG
TABLET
METHOTREXATE (METHOTREXATE DISODIUM) 2.5MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0107545001; AHFS:
APPROVED
2022-01-05
Page 1 of 40 PRODUCT MONOGRAPH PR AURO-METHOTREXATE Methotrexate Tablets USP 2.5 mg methotrexate (as methotrexate disodium) ATC Code: L01BA01 ANTIMETABOLITE AURO PHARMA INC. DATE OF REVISION: 3700 Steeles Avenue West, Suite # 402 May 15, 2023 Woodbridge, Ontario, L4L 8K8, Canada SUBMISSION CONTROL NO: 267435 Page 2 of 40 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................3 SUMMARY PRODUCT INFORMATION .........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ....................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS .................................................................................................12 DRUG INTERACTIONS .................................................................................................15 DOSAGE AND ADMINISTRATION .............................................................................19 OVERDOSAGE ................................................................................................................22 ACTION AND CLINICAL PHARMACOLOGY ............................................................23 STORAGE AND STABILITY .........................................................................................25 SPECIAL HANDLING INSTRUCTIONS .......................................................................25 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................26 PART II: SCIENTIFIC INFORMATION .............................................................................27 PHARMACEUTICAL INFORMATION .........................................................................27 CLINICAL TRIALS ................................................................... Leia o documento completo